Metastatic Non-small Cell Lung Cancer Clinical Trial
Official title:
Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AC0010 in Patients With EGFR T790M Positive Advanced Non Small Cell Lung Cancer Who Progressed on Prior Therapy With EGFR TKIs
Verified date | September 2021 |
Source | Hangzhou ACEA Pharmaceutical Research Co., Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
AC0010 is a novel, potent, small molecule irreversible tyrosine kinase inhibitor (TKI) that selectively targets mutant forms of the epidermal growth factor receptor (EGFR) while sparing wild-type (WT) EGFR. The purpose of the study is to evaluate the pharmacokinetic (PK) and safety profile of oral AC0010; to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of oral AC0010; to assess the safety and efficacy of AC0010 in previously treated mutant EGFR in NSCLC patients with EGFR T790M mutation.
Status | Active, not recruiting |
Enrollment | 368 |
Est. completion date | March 2023 |
Est. primary completion date | December 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria - phase 1: 1. Patients of either gender, aged from 18 years older to 75. 2. Histologically or cytologically confirmed metastatic, or unresectable locally advanced, recurrent NSCLC. 3. At least one measurable disease by CT or MRI, according to RECIST Version 1.1. 4. Failed to the treatment of EGFRTKI with definite state of T790M, or harbored T790M mutation without the treatment of EGFRTKI. 5. Offer biopsy sample to central lab if failed or without the treatment of EGFRTKI. 6. Adequate hematological and physiological functions of heart, lung, liver, and kidney according to definitions given in Appendix D. 7. Any prior treatment (including chemotherapy, radiotherapy, biotherapy and other clinical medicine) must be completed over 28 days or 5 half-lives from the screening. 8. ECOG (Eastern Cooperative Oncology Group) performance status of 0 to 1. 9. NSCLC patients with asymptomatic brain metastasis or drug-controllable brain metastasis. 10. Life expectancy of at least 3 months. 11. Patients should cooperate with investigator to observe adverse events and efficacy. 12. Without other anticancer therapy. 13. Women without pregnancy or breastfeeding. 14. Adequate function of blood coagulation (INR=1.5) 15. Signed consent on an Independent Ethics Committee-approved Informed Consent Form prior to any study-specific evaluation. Exclusion Criteria - Phase 1: 1. No pathology confirmation. 2. HCV positive, active hepatitis B. 3. History of interstitial lung disease related to prior EGFR inhibitor therapy. 4. Positive to HIV antibody or other immunodeficiency disease or organ transplantation. 5. Residue toxicity related to prior therapies > grade 1. 6. BUN or Cr > 1.5 × upper limits of normal. 7. ALT or AST > 2.5 × upper limits of normal, total bilirubin> 1.5 × upper limits of normal. 8. Fever (temperature>38? or any uncontrolled active infections. 9. Patients received high-dose glucocorticoid or any other immunosuppression within 1 month. 10. Any severe or uncontrolled disease, such as mental, neurologic, cardiovascular, respiratory diseases. 11. Patients with symptomatic and untreated brain metastasis. 12. Patients with organic heart disease, cardiac insufficiency, >2 degree heart block, experienced myocardial infarction in 6 months. Abnormal PR, QT, QRS interval (defined as: 12 lead electrocardiogram QT interval correlated to Bazetts (QTcB)>450ms (male) or >470ms (female), PR>240ms, QRS>110ms). 13. Patients receiving medication known to prolong QT interval. 14. Past history of major surgery in 14 days prior to enrollment. 15. Pregnant or lactating women. 16. Any other reasons for the investigator to consider the patient should not participate in the study. Inclusion Criteria - Phase 2: 1. Patients of either gender, aged from 18 years older to 75. 2. Histologically or cytologically confirmed metastatic, or unresectable locally advanced, recurrent NSCLC. 3. At least one measurable disease by CT or MRI, according to RECIST Version 1.1. 4. Failed to the treatment of EGFR-TKI and harbored T790M mutation. 5. Offer biopsy sample to central lab if failed or without the treatment of EGFRTKI. 6. Patients failed the treatment of EGFR-TKI should be treated with only one kind of medicine. Patients with arbored T790M mutation should be treated with only one kind of medicine or never be treated. 7. Comply with the results of laboratory testing. 8. ECOG (Eastern Cooperative Oncology Group) performance status of 0 to 1 and no deterioration in 2 weeks. 9. Life expectancy of more than 12 weeks. 10. Patients should cooperate with investigator to observe adverse events and efficacy. 11. Women without pregnancy. 12. Signed consent on an Independent Ethics Committee-approved Informed Consent Form prior to any study-specific evaluation. Exclusion Criteria - Phase 2: 1. Acute and chronic hepatitis C, active hepatitis B (including positive HBsAg and/or HBeAg; HBcAb and/or positive HBeAb and positive HBV DNA), hepatitis E Virus IgM antibody positive. 2. History of interstitial lung disease related to prior EGFR inhibitor therapy. 3. Positive to HIV antibody or other immunodeficiency disease or organ transplantation. 4. Fever (temperature>38? or any uncontrolled active infections. 5. Patients received high-dose glucocorticoid or any other immunosuppression within 1 month. 6. Any severe or uncontrolled disease, such as mental, neurologic, cardiovascular, respiratory diseases. 7. ECG showed abnormal rhythm, conduction and form, such as complete left bundle branch block, >2 degree heart block, PR interval >250ms, experienced myocardial infarction in 6 months. Risks leading to prolonged QT interval or arrhythmia, such as heart failure, hypokalemia, congenital long QT, long QT family history or sudden death under 40 years old in first degree relatives (12 lead electrocardiogram QT interval correlated to Bazetts (QTcB) > 450ms. 8. Prior history of malignancies other than NSCLC (except cured malignancy such as removed basal-cell carcinoma and carcinoma in situ) within 5 years. 9. Patients with CNS metastasis (except asymptomatic CNS metastasis with stable radiography in 4 weeks and no long-term use of corticosteroid. CNS metastasis focuses =2, maximum diameter of focus <10mm) 10. Radiation field covered more than 30% bone marrow within 4 weeks of enrollment. 11. Lab test of 1ml plasma prove treatment of AZD9291. 12. Patients already received treatment of this research or quite the treatment of this research. Patients treated with 3rd generation of EGFR-TKI (AZD9291, AC0010, BPI-15086, CO-1686, HM61713). 13. Past history of major surgery in 14 days prior to enrollment. 14. Pregnant or lactating women. 15. Patients with uncontrolled pleural effusion and/or pericardial effusion. 16. Any other reasons for the investigator to consider the patient should not participate in the study |
Country | Name | City | State |
---|---|---|---|
China | 307 Hospital of PLA | Beijing | Beijing |
China | Beijing Cancer Hospital | Beijing | Beijing |
China | Cancer Hospital Chinese Academy of Medical Sciences | Beijing | Beijing |
China | Chinese PLA General Hospital | Beijing | Beijing |
China | Peking Union Medical College Hospital | Beijing | Beijing |
China | Jilin Cancer Hospital | Chang Chun | Jilin |
China | Hunan Cancer Hospital | Changsha | Hunan |
China | West China Hospital,Sichuan University | Chendu | Sichuan |
China | Fujian Medical University Union Hospital | Fuzhou | Fujian |
China | Guangdong Provincial People's Hospital | Guangzhou | Guangdong |
China | Sun Yat-sen University Cancer Center | Guangzhou | Guangdong |
China | The First Affiliated Hospital, Zhejiang University | Hangzhou | Zhejiang |
China | The Second Affiliated Hospital of Zhejiang University School of Medicine | Hanzhou | Zhejiang |
China | Jiangsu Cancer Hospital | Nanjing | Jiangsu |
China | Jiangsu Province Hospital | Nanjing | Jiangsu |
China | Nanjing General Hospital of Nanjing Military Command | Nanjing | Jiangsu |
China | Shanghai Chest Hospital | Shanghai | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Hangzhou ACEA Pharmaceutical Research Co., Ltd. | Acea Bio (Hangzhou) Co., Ltd., Guangdong Provincial People's Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | ORR(Objective Response Rate) | To assess the overall objective response rate (ORR) of AC0010 in EGFR T790M mutation-positive patients with advanced non-small cell lung cancer (NSCLC). | Every 6 weeks from time of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 11 months | |
Secondary | DoR (Duration of Response) | To assess the duration of response (DOR) of AC0010 in EGFR T790M mutation-positive patients with advanced non-small cell lung cancer (NSCLC). | Every 6 weeks from time of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 11 months | |
Secondary | PFS (Progression-free survival) | To assess the progression-free survival (PFS) of AC0010 in EGFR T790M mutation-positive patients with advanced non-small cell lung cancer (NSCLC). | Every 6 weeks from time of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 11 months | |
Secondary | DCR (Disease control rate) | To assess the disease control rate (DCR) of AC0010 in EGFR T790M mutation-positive patients with advanced non-small cell lung cancer (NSCLC). | Every 6 weeks from time of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 11 months | |
Secondary | OS (Overall survival) | To assess the overall survival (OS) of AC0010 in EGFR T790M mutation-positive patients with advanced non-small cell lung cancer (NSCLC). | Every 6 weeks from time of first dose until objective disease progression, then every 3 months until death of lost of follow-up, up to approximately 18 months | |
Secondary | EORTC QLQ-C30 and LC-13 questionnaire | To assess the safety of AC0010 in EGFR T790M mutation-positive patients with advanced non-small cell lung cancer (NSCLC). | From screening to the end of survival follow-up, which is assessed though study completion | |
Secondary | Adverse events | To assess the safety of AC0010 in EGFR T790M mutation-positive patients with advanced non-small cell lung cancer (NSCLC). | From screening to 30days after end of treatment, which is assessed through study completion |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02857270 -
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
|
Phase 1 | |
Not yet recruiting |
NCT05985330 -
Pilot Study of the Contribution of Fractional Exhaled Nitric Oxide as a Prognostic Marker of Response to Anti-PD-L1 Immunotherapy in Non-small Cell Lung Cancer
|
||
Recruiting |
NCT05013450 -
Dupilumab_Metastatic NSCLC
|
Phase 1/Phase 2 | |
Recruiting |
NCT05984277 -
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
|
Phase 3 | |
Completed |
NCT03215810 -
Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer
|
Phase 1 | |
Completed |
NCT05675683 -
Real-World Assessment of Clinical Outcomes in Metastatic NSCLC Patients With MET Exon 14 Skipping Mutation and Brain Metastases Treated With Capmatinib
|
||
Active, not recruiting |
NCT02411448 -
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)
|
Phase 3 | |
Recruiting |
NCT04410796 -
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
|
Phase 2 | |
Recruiting |
NCT03300115 -
Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCLC
|
Phase 2 | |
Recruiting |
NCT05635708 -
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
|
Phase 2 | |
Terminated |
NCT03265080 -
A Study of ADXS-NEO Expressing Personalized Tumor Antigens
|
Phase 1 | |
Active, not recruiting |
NCT05226598 -
Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)
|
Phase 3 | |
Withdrawn |
NCT02639234 -
Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT05364073 -
Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations
|
Phase 1 | |
Completed |
NCT03926260 -
Early Assessment of Response to Treatment of Metastatic LUng Tumors Based on CIrculating Tumor DNA
|
N/A | |
Active, not recruiting |
NCT03976375 -
Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)
|
Phase 3 | |
Recruiting |
NCT05546905 -
A Study in Patients With BRAF V600E-mutant Metastatic Non-small Cell Lung Cancer (OCTOPUS)
|
||
Withdrawn |
NCT01936961 -
Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors
|
N/A | |
Recruiting |
NCT06212752 -
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension
|
Phase 3 | |
Recruiting |
NCT05607550 -
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
|
Phase 3 |